<!DOCTYPE html>
<html lang="en" data-theme="light">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Chemotherapy I: Antibiotics - Pharmacology and Pharmacotherapeutics</title>
    
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap" rel="stylesheet">
    
    <link rel="stylesheet" href="../styles/main.css">
    
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams'
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>
    
    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <!-- Floating Table of Contents -->
    <div class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span>
            <span>Contents</span>
        </div>
        <ul class="floating-toc-list">
            <!-- JS will populate this -->
        </ul>
    </div>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>ü¶†</span>
                        <span>Section XII (Part A)</span>
                    </div>
                    <h1 class="document-title">Chemotherapy: General Antibiotics</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Sulfonamides, Penicillins, Cephalosporins, Aminoglycosides & Broad Spectrum Antibiotics</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>90 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- START: Chapter 45 -->
                    <section class="content-section" id="chapter-45">
                        <div class="section-header">
                            <div class="section-number">45</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß™</span>
                                Sulfonamides and Quinolones
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Sulfonamides</h3>
                            <p><strong>Mechanism:</strong> Competitively inhibit <strong>dihydropteroate synthase</strong>, preventing the conversion of PABA to dihydrofolic acid. Bacteriostatic.</p>
                            <p><strong>Cotrimoxazole:</strong> Combination of Sulfamethoxazole + Trimethoprim (5:1 ratio). Sequential blockade of folate synthesis (Trimethoprim inhibits <strong>dihydrofolate reductase</strong>). Bactericidal.</p>

                            <h3>Fluoroquinolones</h3>
                            <p><strong>Mechanism:</strong> Inhibit <strong>DNA Gyrase</strong> (Topoisomerase II) and Topoisomerase IV, preventing DNA supercoiling. Bactericidal.</p>
                            
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <caption>Classification of Fluoroquinolones</caption>
                                    <thead>
                                        <tr>
                                            <th>Generation</th>
                                            <th>Drugs</th>
                                            <th>Activity</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>First</strong></td>
                                            <td>Nalidixic Acid</td>
                                            <td>Urinary antiseptics only (Gram negative).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Second</strong></td>
                                            <td>Ciprofloxacin, Ofloxacin, Norfloxacin</td>
                                            <td>Systemic Gram negative, some Gram positive. Urinary/GI infections.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Third</strong></td>
                                            <td>Levofloxacin, Moxifloxacin</td>
                                            <td>"Respiratory Fluoroquinolones". Enhanced Gram positive (Strep. pneumoniae) and atypical activity.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                            <p><strong>Adverse Effects:</strong> Tendonitis/Tendon rupture (Achilles), QT prolongation (Moxifloxacin), Phototoxicity, CNS effects (dizziness, seizures). <strong>Contraindicated</strong> in pregnancy and children (cartilage damage).</p>
                        </div>
                    </section>
                    <!-- END: Chapter 45 -->

                    <!-- START: Chapter 46 -->
                    <section class="content-section" id="chapter-46">
                        <div class="section-header">
                            <div class="section-number">46</div>
                            <h2 class="section-title">
                                <span class="title-icon">üçÑ</span>
                                Penicillins and Other Gram-Positive Active Antibiotics
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Mechanism:</strong> Beta-lactam antibiotics inhibit <strong>transpeptidase</strong>, preventing cross-linking of peptidoglycan in the bacterial cell wall. Bactericidal.</p>

                            <h3>Classification of Penicillins</h3>
                            <div class="grid grid-2">
                                <div class="grid-item">
                                    <h4>Natural Penicillins</h4>
                                    <p><strong>Benzylpenicillin (Penicillin G):</strong> Acid labile (IV/IM). Short duration. Effective against Strep, Pneumococci, Meningococci, Treponema, Clostridia.<br>
                                    <strong>Repository Forms:</strong> Procaine Penicillin (12-24 hrs), Benzathine Penicillin (3-4 weeks, for Rheumatic fever/Syphilis prophylaxis).</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Acid Resistant</h4>
                                    <p><strong>Penicillin V:</strong> Can be given orally. Less potent.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Penicillinase Resistant</h4>
                                    <p><strong>Cloxacillin, Dicloxacillin, Nafcillin:</strong> Resistant to staphylococcal beta-lactamase. Drug of choice for MSSA.</p>
                                </div>
                                <div class="grid-item">
                                    <h4>Extended Spectrum</h4>
                                    <p><strong>Aminopenicillins:</strong> Ampicillin, Amoxicillin (Better absorption). Active against some Gram -ve (E. coli, H. flu).<br>
                                    <strong>Antipseudomonal:</strong> Carbenicillin, Ticarcillin, Piperacillin. (Used with aminoglycosides).</p>
                                </div>
                            </div>

                            <p><strong>Beta-lactamase Inhibitors:</strong> Clavulanic acid, Sulbactam, Tazobactam. Combined with penicillins (e.g., Amoxicillin + Clavulanate) to protect the ring from destruction by bacterial enzymes.</p>

                            <h3>Macrolides</h3>
                            <p><strong>Erythromycin, Clarithromycin, Azithromycin, Roxithromycin.</strong>
                            <br><strong>Mechanism:</strong> Bind to <strong>50S ribosome</strong>, inhibiting protein synthesis. Bacteriostatic.
                            <br><strong>Uses:</strong> Atypical pneumonia (Mycoplasma, Chlamydia, Legionella), Pertussis, Diphtheria, H. pylori (Clarithromycin), Alt. for Penicillin allergy.
                            <br><strong>Adverse Effects:</strong> GI upset (motilin receptor stimulation), Cholestatic jaundice (Erythromycin estolate), QT prolongation, CYP450 inhibition (drug interactions).</p>

                            <h3>Other Gram-Positive Active Drugs</h3>
                            <ul>
                                <li><strong>Clindamycin (Lincosamide):</strong> Similar mechanism to macrolides. Excellent for anaerobes (B. fragilis) and Osteomyelitis (bone penetration). Risk: <strong>Pseudomembranous colitis</strong> (C. difficile).</li>
                                <li><strong>Vancomycin (Glycopeptide):</strong> Inhibits cell wall synthesis. Drug of choice for <strong>MRSA</strong> and C. difficile (oral). Toxicity: "Red Man Syndrome" (histamine release), Nephrotoxicity, Ototoxicity.</li>
                                <li><strong>Linezolid (Oxazolidinone):</strong> Inhibits protein synthesis (initiation). For VRSA, VRE. Risk: Thrombocytopenia.</li>
                                <li><strong>Daptomycin:</strong> Lipopeptide. Depolarizes membrane. For MRSA skin infections. Inactivated by lung surfactant (not for pneumonia).</li>
                            </ul>
                        </div>
                    </section>
                    <!-- END: Chapter 46 -->

                    <!-- START: Chapter 47 -->
                    <section class="content-section" id="chapter-47">
                        <div class="section-header">
                            <div class="section-number">47</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü¶†</span>
                                Aminoglycosides
                            </h2>
                        </div>

                        <div class="content-card">
                            <p><strong>Streptomycin, Gentamicin, Tobramycin, Amikacin, Netilmicin, Neomycin.</strong></p>

                            <h3>General Properties</h3>
                            <ul>
                                <li><strong>Mechanism:</strong> Bind to <strong>30S ribosome</strong>, causing misreading of mRNA. Bactericidal.</li>
                                <li><strong>Spectrum:</strong> Aerobic Gram-negative bacilli (Pseudomonas, E. coli, Klebsiella). Ineffective against anaerobes.</li>
                                <li><strong>Pharmacokinetics:</strong> Polar cations. Not absorbed orally (given IM/IV). Excreted unchanged by kidney.</li>
                                <li><strong>Toxicity (The "O-N-N" triad):</strong>
                                    <ul>
                                        <li><strong>Ototoxicity:</strong> Vestibular (Streptomycin, Gentamicin) or Cochlear/Auditory (Amikacin, Neomycin). Irreversible.</li>
                                        <li><strong>Nephrotoxicity:</strong> Acute tubular necrosis (Reversible).</li>
                                        <li><strong>Neuromuscular Blockade:</strong> Curare-like effect.</li>
                                    </ul>
                                </li>
                            </ul>

                            <h3>Specific Agents</h3>
                            <p><strong>Streptomycin:</strong> First line for TB, Plague, Tularemia, Brucellosis.</p>
                            <p><strong>Gentamicin:</strong> Workhorse for serious Gram -ve infections.</p>
                            <p><strong>Amikacin:</strong> Resistant to modifying enzymes. Used for MDR-TB and gentamicin-resistant organisms.</p>
                            <p><strong>Neomycin:</strong> Too toxic for systemic use. Used topically (skin/eye) or orally for gut sterilization (hepatic coma).</p>
                        </div>
                    </section>
                    <!-- END: Chapter 47 -->

                    <!-- START: Chapter 48 -->
                    <section class="content-section" id="chapter-48">
                        <div class="section-header">
                            <div class="section-number">48</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Cephalosporins and Other Beta-Lactams
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Cephalosporins</h3>
                            <p>Classified by generations. As generation increases, Gram-negative activity increases, Gram-positive activity decreases (generally), and CNS penetration improves.</p>
                            
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Generation</th>
                                            <th>Parenteral</th>
                                            <th>Oral</th>
                                            <th>Key Uses</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>First</strong></td>
                                            <td>Cefazolin</td>
                                            <td>Cephalexin</td>
                                            <td>Surgical prophylaxis, skin/soft tissue (Staph/Strep).</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Second</strong></td>
                                            <td>Cefuroxime</td>
                                            <td>Cefaclor</td>
                                            <td>Respiratory infections, mixed infections.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Third</strong></td>
                                            <td>Ceftriaxone, Cefotaxime, Ceftazidime</td>
                                            <td>Cefixime, Cefpodoxime</td>
                                            <td>Meningitis (Ceftriaxone), Pseudomonas (Ceftazidime), Typhoid, Gonorrhoea.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Fourth</strong></td>
                                            <td>Cefepime</td>
                                            <td>-</td>
                                            <td>Resistant Gram -ve, Pseudomonas, Neutropenic fever.</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Fifth</strong></td>
                                            <td>Ceftaroline</td>
                                            <td>-</td>
                                            <td><strong>MRSA</strong> activity.</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                            <p><strong>Adverse Effects:</strong> Hypersensitivity (cross-reactivity with penicillin ~10%), Nephrotoxicity (synergy with aminoglycosides), Bleeding/Disulfiram-like reaction (Cefoperazone, Cefamandole - methylthiotetrazole group).</p>

                            <h3>Carbapenems</h3>
                            <p><strong>Imipenem, Meropenem.</strong>
                            <br>Broadest spectrum beta-lactams. Resistant to beta-lactamases.
                            <br><strong>Imipenem:</strong> Metabolised by renal dehydropeptidase I (DHP-I). Always combined with <strong>Cilastatin</strong> (DHP-I inhibitor) to prevent nephrotoxicity. Risk of seizures.
                            <br><strong>Meropenem:</strong> Stable to DHP-I. Less seizure risk.</p>

                            <h3>Monobactams</h3>
                            <p><strong>Aztreonam.</strong> Active <em>only</em> against aerobic Gram-negative bacteria (like aminoglycosides). Safe in penicillin-allergic patients (no cross-reactivity).</p>
                        </div>
                    </section>
                    <!-- END: Chapter 48 -->

                    <!-- START: Chapter 49 -->
                    <section class="content-section" id="chapter-49">
                        <div class="section-header">
                            <div class="section-number">49</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Tetracyclines and Chloramphenicol
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Tetracyclines</h3>
                            <p><strong>Tetracycline, Doxycycline, Minocycline, Tigecycline.</strong>
                            <br><strong>Mechanism:</strong> Bind to <strong>30S ribosome</strong>. Bacteriostatic. Broad spectrum (Rickettsia, Chlamydia, Mycoplasma, Spirochetes).
                            <br><strong>Pharmacokinetics:</strong> Chelated by Ca, Mg, Fe (avoid milk/antacids). Doxycycline is safe in renal failure (fecal excretion).
                            <br><strong>Adverse Effects:</strong> GI upset, Phototoxicity, Teeth discoloration/Bone deformity (Contraindicated in pregnancy and children &lt;8 yrs), Hepatotoxicity (in pregnancy).</p>

                            <h3>Chloramphenicol</h3>
                            <p><strong>Mechanism:</strong> Binds to <strong>50S ribosome</strong> (inhibits peptidyl transferase). Bacteriostatic.
                            <br><strong>Adverse Effects:</strong>
                            <br>1. <strong>Bone Marrow Depression:</strong> Dose-related (reversible) and Idiosyncratic Aplastic Anemia (irreversible, fatal).
                            <br>2. <strong>Gray Baby Syndrome:</strong> In neonates (lack of glucuronyl transferase). Vomiting, flaccidity, cyanosis, shock.
                            <br><strong>Uses:</strong> Meningitis (excellent CNS penetration), Typhoid (historical), Anaerobes. Used as reserve drug due to toxicity.</p>
                        </div>
                    </section>
                    <!-- END: Chapter 49 -->
                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="section-11.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">Section XI: Oxytocics</div>
                        </a>
                        
                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>12a</span>
                                <span class="progress-separator">/</span>
                                <span>16</span>
                            </div>
                        <a href="../index.html" class="nav-button nav-button--large">
                            <div class="nav-label">Go to</div>
                            <div class="nav-title">Index</div>
                        </a>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 75%;"></div>
                            </div>
                            <div class="progress-label">Section 12 (Part A)</div>
                        </div>
                        
                        <a href="section-12b.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Section XII-B: Specific Infections</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <script src="../js/theme.js"></script>
    <script src="../js/navigation.js"></script>
    <script src="../js/interactions.js"></script>
</body>
</html>